NERV - Minerva Neurosciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Minerva Neurosciences, Inc.

1601 Trapelo Road
Suite 286
Waltham, MA 02451
United States
617-600-7373
http://www.minervaneurosciences.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Rémy LuthringerExec. Chairman & CEO680.15kN/A1961
Mr. Geoffrey Robin Race FCMA, MBAExec. VP, CFO & Chief Bus. Officer588.15kN/A1961
Mr. Joseph ReillySr. VP & COO461kN/A1975
Mr. Richard RussellPresN/AN/AN/A
Mr. Frederick W. Ahlholm CPASr. VP & Chief Accounting OfficerN/AN/A1966
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Corporate Governance

Minerva Neurosciences, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.